文献速递前列腺癌

前列腺癌雄激素轴靶向治疗患者胃肠道微生物组成差异

Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-07-09

本研究采用横断面设计,对30名健康男性及不同临床状态前列腺癌患者行粪便16S rDNA测序,发现口服雄激素受体轴靶向治疗(ATT)者肠道微生物组成存在显著差异,包括与抗PD-1免疫治疗应答相关的Akkermansia muciniphila和Ruminococcaceae spp.丰度增加,且粪便微生物中类固醇生物合成相关细菌基因通路富集。

要点

  • 前列腺癌诊断与肠道微生物α多样性显著差异相关。
  • 口服ATT者肠道中Akkermansia muciniphila和Ruminococcaceae spp.丰度更高。
  • 口服ATT者粪便微生物类固醇激素生物合成基因通路富集。

核心结论

  • 接受口服ATT的前列腺癌患者胃肠道微生物组成存在可测量的差异。

研究设计与样本

  • 横断面研究,纳入30名健康男性志愿者及不同临床状态(局限、生化复发、转移)的前列腺癌患者,行粪便16S rDNA扩增子测序,并用PICRUSt进行功能推断。

主要发现

  • 前列腺癌诊断与未诊断男性间肠道微生物α多样性存在显著差异。
  • 口服ATT者肠道中与抗PD-1免疫治疗应答相关的Akkermansia muciniphila和Ruminococcaceae spp.丰度增加。
  • 口服ATT者粪便微生物中类固醇生物合成和类固醇激素生物合成相关细菌基因通路富集。

临床怎么用

  • 提示口服ATT可能改变肠道微生物,进而影响ATT临床应答或未来免疫治疗抗肿瘤效应。
  • 需开展更大规模纵向研究验证上述关联。

局限性

  • 横断面设计无法确定因果关系。
  • 样本量较小(30例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is well known that the gastrointestinal (GI) microbiota can influence the metabolism, pharmacokinetics, and toxicity of cancer therapies. Conversely, the effect of cancer treatments on the composition of the GI microbiota is poorly understood. We hypothesized that oral androgen receptor axis-targeted therapies (ATT), including bicalutamide, enzalutamide, and abiraterone acetate, may be associated with compositional differences in the GI microbiota. METHODS: We profiled the fecal microbiota in a cross-sectional study of 30 patients that included healthy male volunteers and men with different clinical states of prostate cancer (i.e., localized, biochemically recurrent, and metastatic disease) using 16S rDNA amplicon sequencing. Functional inference of identified taxa was performed using PICRUSt. RESULTS: We report a significant difference in alpha diversity in GI microbiota among men with versus without a prostate cancer diagnosis. Further analysis identified significant compositional differences in the GI microbiota of men taking ATT, including a greater abundance of species previously linked to response to anti-PD-1 immunotherapy such as Akkermansia muciniphila and Ruminococcaceae spp. In functional analyses, we found an enriched representation of bacterial gene pathways involved in steroid biosynthesis and steroid hormone biosynthesis in the fecal microbiota of men taking oral ATT. CONCLUSIONS: There are measurable differences in the GI microbiota of men receiving oral ATT. We speculate that oral hormonal therapies for prostate cancer may alter the GI microbiota, influence clinical responses to ATT, and/or potentially modulate the antitumor effects of future therapies including immunotherapy. Given our findings, larger, longitudinal studies are warranted.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Sfanos KS, Markowski MC, Peiffer LB, et al. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 2018. PMID: 29988102. doi:10.1038/s41391-018-0061-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。